Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pioglitazone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 14/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | RXRA | P19793 | 1/20 | 1.00 |
| ▸ | MPC2 | O95563 | 1/20 | 0.66 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.53 |
| ▸ | PPARA | Q07869 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pioglitazone SCHEMBL21843 | 1.00 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL1162192 | 1.00 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL29759383 | 1.00 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL29591932 | 1.00 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL3689044 | 1.00 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL611563 | 1.00 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL1489588 | 1.00 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL4426214 | 0.99 | PPARG (0.98) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL4121 | 0.99 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL1162440 | 0.99 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8911781-B2 | Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides | INVENTIA HEALTHCARE PRIVATE LIMITED (IN) | 2014-12-16 | — | — | US | disclosed |
| EP-1515701-B1 | PROCESS FOR THE MANUFACTURE OF MULTILAYER TABLET COMPOSITIONS COMPRISING THIAZOLIDINEDIONE AND BIGUANIDE | INVENTIA HEALTHCARE PRIVATE LTD (IN) | 2014-09-17 | — | — | EP | disclosed |
| US-8541456-B2 | Roflumilast for the treatment of diabetes mellitus type 2 | TAKEDA GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| CN-101511364-B | Combination treatment for diabetes mellitus | NYCOMED GMBH | 2012-08-15 | — | — | CN | disclosed |
| US-20110269750-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | NYCOMED GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| US-8017633-B2 | Administering [3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)benzamide; hypertension, hyperlipidemia, hyperuricemia, gout and hypercoagulability | NYCOMED GMBH (DE) | 2011-09-13 | — | — | US | disclosed |
| EP-2213289-A1 | Combination treatment for diabetes mellitus | Nycomed GmbH (DE) | 2010-08-04 | — | — | EP | disclosed |
| US-20100179131-A1 | Combination treatment for diabetes mellitus | NYCOMED GMBH (DE) | 2010-07-15 | — | — | US | disclosed |
| CN-101511364-A | Combination treatment for diabetes mellitus | NYCOMED GMBH (DE) | 2009-08-19 | — | — | CN | disclosed |
| US-20080214625-A1 | Roflumilast for the Treatment of Diabetes Mellitus | KONINKLIJKE HILIPS ELECTRONICS, N.V. (NL) | 2008-09-04 | — | — | US | disclosed |
| US-20060057202-A1 | Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them | THEMIS LABORATORIES PRIVATE LIMITED (IN) | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214625-A1 | Roflumilast for the Treatment of Diabetes Mellitus | NOS3, PLAT, PTGIS | PPARG 977/4885CYP3A4 421/4885RXRA 1620/4885 |
| US-20110269750-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | PPARD, PPARA, PPARG | PPARG 3/4885CYP3A4 553/4885RXRA 167/4885 |
| US-20100179131-A1 | Combination treatment for diabetes mellitus | GPR119, GLP1R, MTNR1B | PPARG 149/4885CYP3A4 328/4885RXRA 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.